Cancer Advocacy Group of Louisiana (CAGLA)’s Post
More Relevant Posts
-
Chadwick K. Landry is President and Executive Director of CAGLA. Chad has over 20 years of experience working in the finance industry. He began his career working for 3 years as a financial analyst in Enron North America’s Power Private Equity Group in Houston, Texas. He spent the next fourteen years working as Senior Institutional Equity Research Salesman for Capital One Southcoast and Iberia Capital Partners. In this role, he advised hedge funds and mutual funds on equity trading strategies associated with the Energy, Industrials, Utilities, and Consumer Sector(s) of the U.S. economy. Chad is currently the Managing Member and a Portfolio Manager at Poydras Capital Partners which is a Registered Investment Advisor (RIA) based in Metairie, Louisiana. Chad holds a B.S. in Finance from Louisiana State University. He also currently holds his Series 7, 63, and 65 licenses. Chad lives in Metairie, Louisiana. He spends his free time reading, running, traveling, boxing, and raising money for his local cancer nonprofit organization the New Orleans Lympho-Maniac Cancer Fund.
-
-
Tulane Colorectal Surgeon and CAGLA Scientific Advisory Board Member Dr Jackie Turner got the opportunity last week to present to President Joe Biden. Opportunity of a lifetime! Congrats Dr Turner. We are super proud of you.
This week, our Director Renee Wegrzyn had the honor of standing alongside President Joe Biden and First Lady Dr. Jill Biden when they announced up to $150 million in ARPA-H awards to eight trailblazing teams selected for our PSI program to create new technology that ensures perfect cancer tumor removal. These performer teams are stepping closer to answering, “what if surgeries fixed problems flawlessly, the first time?” https://lnkd.in/eX3ABF6z During the event in New Orleans where President Biden and the First Lady delivered remarks on the announcement, President Biden said, “When Jill and I reignited the #CancerMoonshot in our administration, we were determined to launch this new outfit called ARPA-H. And that’s what we did… ARPA-H has so far committed more than $400 Million to ending cancer as we know it. A year ago, ARPA-H set its sights on a big idea, calling on researchers and innovators to pioneer new techniques and technologies to make cancer removal more precise, accurate, and successful. Imagine cancer surgery that removes all of the tumor the first time, without harming healthy cells… Today we’re announcing $150 Million ARPA-H funding for some of the nation’s cutting-edge cancer research institutions.”
-
-
Oh, what an evening at Copeland Tower! CAGLA's board of trustees and scientific advisory board members held a thrilling quarterly meeting! The best part? We had speakers from Rise St. James who shared their inspiring stories battling the Petrochemical Industry in Cancer Alley! Led by Sharon Lavigne, 2021’s Goldman Environmental Prize winner, Rise St. James galvanized community opposition and successfully defeated the construction of a $1.25 billion plastics manufacturing plant in 2018. CAGLA and Rise St. James hope to collaborate in the future in an effort to create new Cancer prevention and early detection programs to treat the current residents in both St. John and St. James parishes. We're in full swing planning the 2025 CAGLA NeauxCancer Conference, happening 3/27 - 3/29 at the Roosevelt Hotel, New Orleans. We're expanding with 4 exciting CME/CE Tracks and 1 Investment/Innovation Track. Our 2025 Conference Registration Website, featuring an updated Sponsor Brochure, goes live soon. Get ready for an amazing event! Best, Chad
-
-
-
-
-
+8
-
-
Dr. Marc Matrana and I had an opportunity today to represent Cancer Advocacy Group of Louisiana at the Biden Cancer Moonshot Initiative event at Tulane in New Orleans. At this event President Biden announced that Dr Brown (Tulane Cancer Research/Lead Investigator) is the recipient of a $23 Million Advanced Research Projects Agency for Health (ARPA-H) grant which is a Biden cancer initiative. Dr Brown’s research is looking at a device he developed that assesses real time pathology specimen margins. This is groundbreaking in that the device can potentially give surgeons more information about their resection margins during the operation. This would allow surgeons to have better intraop decision making hopefully reducing local recurrence rates. #BidenCancerMoonshot #CaglaStrong
-
-
-
-
-
+3
-
-
Dr Juneja giving another Master Class on another complex medical topic - biomarker testing! Nobody can break it down better then Dr Juneja. His communication skills are truly a gift.
Hematologist & Medical Oncologist | Host of 'Target: Cancer Podcast' | A.I. Techno-Optimist | Keynote Speaker | Editorial Board Member 'AI in Precision Oncology' | Co-Founder of Medfluencers & TensorBlack AI
yall, circulating tumor DNA, is NOT.. circulating tumor. period. your circulating blood is a CLOSED system—meaning it all circulates from left side of heart, to right side. with EVERY. HEART BEAT. That also means it goes through EVERY cell and organ in your body, well because, that's how cells get their nutrition, after all. So, when an area has dead cells—because ALL cells outside of the central nervous system & heart... die. aka 'turn OVER'--with others replicating to replace them—those cells have contents. These BLUE prints, otherwise, called DNA. Thats why why we look for the blue prints—of POTENTIAL, even stage 1 tumors somewhere we don’t know where to look, or, to ensure you’re in a remission (aka MRD). #cancer #bloodtest #MRD #ctDNA
-
The 2025 CAGLA NeauxCancer Conference, initially scheduled for late January, has been rescheduled to March 27th-29th to accommodate our sponsors' national sales meetings. The venue remains unchanged - the Roosevelt Hotel, New Orleans. We regret any inconvenience caused and appreciate your understanding. For further inquiries or concerns about the 2025 CAGLA Conference, feel free to reach out. The conference registration website and agenda will be available soon. We eagerly await your participation. Regards, Chad
-
Congrats Guardant Health on FDA approval of your Shield Blood Test!
Blood testing has the potential to transform #ColorectalCancer screening, and the FDA approval of our Shield test for people age 45+ at average risk is a major step forward for the 50 million people in the U.S. who are not up to date with screening. Thank you to our clinical and medical partners, to the people who participate in our studies and to our team at Guardant for making this moment possible! More details: https://lnkd.in/expTfVEJ
-
Wanted to share Guardant Health's (GH) big announcement below. We've gotten to know the GH team really well thru their continued involvement/title sponsorship of our Annual CAGLA NeauxCancer Conference. They are good people and true professionals who are committed to the fight of eradicating cancer across the globe. They continue to push forward with innovative new products that truly make a difference in cancer patients lives. See below for detail.
Today we announced a major upgrade to our market-leading Guardant360 test. It now covers 10 times more genomic biomarkers, including all guideline-recommended ones across advanced solid tumors, and quantifies tumor burden with 10 times higher sensitivity. “Guardant360 is the leading liquid biopsy test for patients with advanced cancer, and this major upgrade through our Guardant Infinity smart liquid biopsy platform enables us to give oncologists a much more complete view of cancer,” said co-CEO Helmy Eltoukhy. Read the full release: https://lnkd.in/en5UR-ag
-
-
Great msg from GH. Get your colorectal screening test b/c it might save your life.
Colorectal cancer is highly treatable if caught early. Yet, despite having screening options available, a staggering 50 million people – approximately one in three eligible Americans – are not up to date with recommended screening. Recently an FDA committee endorsed a new blood test as a primary non-invasive screening option. It has the potential to motivate more patients to be screened and ultimately save more lives. We, the undersigned, urge policymakers, health care professionals, and our fellow advocates to rally behind this groundbreaking technology and give patients more screening options. Signatories: Colorectal Cancer Alliance, Alliance for Women's Health & Prevention, Cancer Advocacy Group of Louisiana (CAGLA), Colon Cancer Stars, First Ladies Health Initative, Global Colon Cancer Association, GI Cancers Alliance, MAN UP TO CANCER, The Raymond Foundation, Inc., Colon Cancer Coalition, PALTOWN Development Foundation, The Blue Hat Foundation, One Cancer Place
